Access all of the content
It was a delight to be able to speak with Dr Carlos Chaccour (University of Barcelona, Barcelona, Spain) about the controversy currently surrounding the use of ivermectin for the treatment of COVID-19.
His presentation entitled Ivermectin and COVID: what’s going on? was presented at the ISNTD d3 2021 Virtual Congress, 24-25 February.
- Could you give us a brief overview of the controversy surrounding the use of ivermectin for the treatment of COVID-19? (0:49)
- What evidence has been generated to date to help support the case for and against the drug’s use? (3:53)
- What further evidence is emerging on the efficacy of ivermectin in this indication? (6:36)
Disclosures: Dr Carlos Chaccour has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media
Filmed in coverage of ISNTD d3 2021 Virtual Conference.
Share this Video
Related Videos In COVID-19
Jeffrey Strich: Phase 2 Trial Results Investigating Fostamatinib for the treatment of COVID-19
It was a great pleasure to meet with Jeffrey Strich (National Institutes of Health Clinical Center, Bethesda, MD, USA) to discuss the findings from a recent phase 2 study investigating fostamatinib for the treatment of hospitalized adults with COVID-19. Useful Resources: Published data available here: Fostamatinib for the treatment of hospitalized adults with COVID-19 A […]
Evangelos Giamarellos-Bourboulis: Phase 3 SAVE-MORE Study Results Investigating Anakinra in the Treatment of Severe COVID-19
It was a great pleasure to meet with Prof. Evangelos Giamarellos-Bourboulis (Attikon University Hospital, Athens, Greece) to discuss phase 3 SAVE-MORE study assessing the effect of anakinra for the treatment of patients with COVID-19 pneumonia. Useful Resources: Publication available to access here: https://www.nature.com/articles/s41591-021-01499-z Questions: Could you give us a brief overview of the role of […]
Rifaat Safadi, EASL ILC 2021: Impact of Liver Disease on SARS-CoV-2 Vaccine Response
It was a pleasure to speak with Prof. Rifaat Safadi (Hadassah University Hospital, Ein Kerem, Jerusalem) about the impact of advanced chronic liver disease on the efficacy of the Pfizer and Moderna mRNA SARS-CoV-2 vaccines. His abstract entitled ‘Elderly with advanced liver fibrosis had lower response to Pfizer’s SARS-CoV-2 vaccine response’ was presented at EASL […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!